AR and posterior cortical atrophy: Specifically, a subpopulation of AR- and neuroendocrine (NE)-null PCa cells, double-null PCa (DNPC), has been observed frequently in patients treated with abiraterone (ABI) and enzalutamide (ENZ), directly contributing to the incidence and mortality of metastatic CRPC (mCRPC)10.